Literature DB >> 23410544

Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation).

Hessel F Groenveld1, Jan G P Tijssen, Harry J G M Crijns, Maarten P Van den Berg, Hans L Hillege, Marco Alings, Dirk J Van Veldhuisen, Isabelle C Van Gelder.   

Abstract

OBJECTIVES: This study sought to investigate differences in outcome between patients treated with successful strict, failed strict, and lenient rate control.
BACKGROUND: The RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation) study showed no difference in outcome between lenient and strict rate control in patients with permanent atrial fibrillation (AF). However, in the strict group not all patients achieved the pre-defined heart rate target.
METHODS: The primary outcome was a composite of cardiovascular morbidity and mortality. For the current analysis outcome events were analyzed from end of the dose-adjustment phase until end of follow-up (median 2.9 years [interquartile range: 2.4 to 3.0 years]). Of 614 patients, 608 completed the dose-adjustment phase-301 in the strict (resting heart rate <80 beats/min, and during moderate exercise <110 beats/min) and 307 in the lenient group (resting heart rate <110 beats/min). In the strict group, 203 of 301 patients achieved the rate control target, and 98 failed.
RESULTS: Heart rate was different after the dose-adjustment phase between the successful strict (72 ± 7 beats/min), failed strict (86 ± 14 beats/min), and lenient (93 ± 8 beats/min) group (p < 0.001) and remained significantly different during follow-up. The primary outcome was reached in 27 of 203 (14.2% KM estimate) in the successful strict versus 14 of 98 (15%) in the failed strict versus 35 of 307 (12.1%) in the lenient group (p = 0.5). The components of the primary outcome and quality of life were similar in the groups.
CONCLUSIONS: In patients with permanent AF, successful strict rate control does not improve outcome. Therefore, lenient rate control might be frontline therapy.
Copyright © 2013 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23410544     DOI: 10.1016/j.jacc.2012.11.038

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

1.  Rate control in atrial fibrillation, insight into the RACE II study.

Authors:  H F Groenveld; H J G M Crijns; J G P Tijssen; M Alings; H L Hillege; Y S Tuininga; M P Van den Berg; D J Van Veldhuisen; I C Van Gelder
Journal:  Neth Heart J       Date:  2013-04       Impact factor: 2.380

2.  Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure?

Authors:  Laurent Fauchier; Guillaume Laborie; Nicolas Clementy; Dominique Babuty
Journal:  Card Fail Rev       Date:  2016-05

3.  [Therapeutic management of non-valvular atrial fibrillation. Update 2013].

Authors:  K Bode; P Sommer; A Bollmann; G Hindricks
Journal:  Herz       Date:  2013-11       Impact factor: 1.443

4.  Current Evidence and Recommendations for Rate Control in Atrial Fibrillation.

Authors:  Abhishek Maan; Moussa Mansour; Jeremy N Ruskin; E Kevin Heist
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-04

5.  Retrospective Evaluation of the Effect of Heart Rate on Survival in Dogs with Atrial Fibrillation.

Authors:  B Pedro; J Dukes-McEwan; M A Oyama; M S Kraus; A R Gelzer
Journal:  J Vet Intern Med       Date:  2017-12-04       Impact factor: 3.333

Review 6.  Arrhythmogenic Substrates for Atrial Fibrillation in Obesity.

Authors:  Ellen R Lubbers; Morgan V Price; Peter J Mohler
Journal:  Front Physiol       Date:  2018-10-22       Impact factor: 4.566

Review 7.  Avoiding permanent atrial fibrillation: treatment approaches to prevent disease progression.

Authors:  Ashish Shukla; Anne B Curtis
Journal:  Vasc Health Risk Manag       Date:  2013-12-16

Review 8.  Managing atrial fibrillation in the very elderly patient: challenges and solutions.

Authors:  Nikolaos Karamichalakis; Konstantinos P Letsas; Konstantinos Vlachos; Stamatis Georgopoulos; Athanasios Bakalakos; Michael Efremidis; Antonios Sideris
Journal:  Vasc Health Risk Manag       Date:  2015-10-27

9.  A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.

Authors:  Dipak Kotecha; Melanie Calvert; Jonathan J Deeks; Michael Griffith; Paulus Kirchhof; Gregory Yh Lip; Samir Mehta; Gemma Slinn; Mary Stanbury; Richard P Steeds; Jonathan N Townend
Journal:  BMJ Open       Date:  2017-07-20       Impact factor: 2.692

10.  Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).

Authors:  Anne-Catherine Pouleur; Stefan Anker; Dulce Brito; Oana Brosteanu; Dirk Hasenclever; Barbara Casadei; Frank Edelmann; Gerasimos Filippatos; Damien Gruson; Ignatios Ikonomidis; Renaud Lhommel; Masliza Mahmod; Stefan Neubauer; Alexandre Persu; Bernhard L Gerber; Stefan Piechnik; Burkert Pieske; Elisabeth Pieske-Kraigher; Fausto Pinto; Piotr Ponikowski; Michele Senni; Jean-Noël Trochu; Nancy Van Overstraeten; Rolf Wachter; Jean-Luc Balligand
Journal:  ESC Heart Fail       Date:  2018-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.